| 3.37 -0.11 (-3.16%) | 09-15 13:29 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.93 | 1-year : | 7.24 |
| Resists | First : | 5.08 | Second : | 6.2 |
| Pivot price | 3.68  |
|||
| Supports | First : | 3.26 | Second : | 2.71 |
| MAs | MA(5) : | 3.45 |
MA(20) : | 4.01 |
| MA(100) : | 5.8 |
MA(250) : | 7.08 |
|
| MACD | MACD : | -0.6  |
Signal : | -0.6 |
| %K %D | K(14,3) : | 8 |
D(3) : | 6.3 |
| RSI | RSI(14): 28.4 |
|||
| 52-week | High : | 11.97 | Low : | 3.26 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ADXN ] has closed above bottom band by 8.6%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.7 - 3.72 | 3.72 - 3.74 |
| Low: | 3.22 - 3.24 | 3.24 - 3.26 |
| Close: | 3.44 - 3.47 | 3.47 - 3.51 |
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
Fri, 04 Sep 2026
Addex Therapeutics (ADXN) cuts CMO's option strike price - Stock Titan
Fri, 04 Sep 2026
Addex Therapeutics (ADXN) resets director equity at $0.032 strike - Stock Titan
Fri, 04 Sep 2026
Addex (NASDAQ: ADXN) CEO now holds over 19M shares after option reset - Stock Titan
Fri, 04 Sep 2026
Addex Therapeutics Ltd (NASDAQ: ADXN) Share Price, ADXN Stock News, ADXN Share Price & Updates - kalkine.ca
Fri, 04 Sep 2026
Director at Addex (ADXN) reprices option and 219,561 shares - Stock Titan
Tue, 01 Sep 2026
Timothy Mark Dyer Discloses 8.98% Stake in Addex Therapeutics (NASDAQ: ADXN) - Kalkine Media
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 808870 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.69e+006 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -6 % |
| Return on Assets (ttm) | 238.8 % |
| Return on Equity (ttm) | -23.6 % |
| Qtrly Rev. Growth | 109500 % |
| Gross Profit (p.s.) | -45.52 |
| Sales Per Share | -62.39 |
| EBITDA (p.s.) | -225622 |
| Qtrly Earnings Growth | -8.9 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 1.54 |
| Dividend | 0 |
| Forward Dividend | 7080 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|